Trial Profile
Clinical Outcome and Patient Characteristics in Non-Small-Cell Lung Cancer with Epidermal growth factor receptor mutations (EGFRm+) receiving Gefitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2018
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Sep 2018 New trial record